KOD Insider Trading
Insider Ownership Percentage: 45.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $12,452.86
Kodiak Sciences Insider Trading History Chart
This chart shows the insider buying and selling history at Kodiak Sciences by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Kodiak Sciences Share Price & Price History
Current Price: $2.63
Price Change: ▼ Price Decrease of -0.185 (-6.58%)
As of 04/1/2025 04:41 PM ET
Kodiak Sciences Insider Trading History
Kodiak Sciences Institutional Trading History
Data available starting January 2016
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Read More on Kodiak Sciences
Volume
312,603 shs
Average Volume
355,665 shs
Market Capitalization
$138.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.26
Who are the company insiders with the largest holdings of Kodiak Sciences?